Paper1707342
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.
Günthert U and 9 others. Cell, 1991. Cited by 1,645 papers, by iCite.
Cite this record
ConductScience Library. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Papers, record 1707342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1707342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasm Metastasis | Major topic |
| Receptors, Lymphocyte Homing | Major topic |
| Amino Acid Sequence | |
| Animals | |
| Antibodies, Monoclonal | |
| Antibodies, Neoplasm | |
| Antibody Specificity | |
| Base Sequence | |
| Cloning, Molecular | |
| DNA, Neoplasm | |
| Epitopes | |
| Molecular Sequence Data | |
| RNA, Messenger | |
| RNA, Neoplasm | |
| Rats | |
| Restriction Mapping | |
| Sequence Homology, Nucleic Acid | |
| Tumor Cells, Cultured |
Source PubMed
Cited by497
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,645 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42504052 | Overcoming Radiation Resistance: Ferroptosis Induction to Sensitize Solid Tumors to Radiation Therapy. | Cancer Med | 2026 | https://conductscience.org/library/papers/42504052 | PubMed |
| 42353077 | CD44-Hyaluronan-Dependent Monocyte Rolling. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353077 | PubMed |
| 42074287 | Chemokine-Independent VLA-4/VCAM-1-Mediated Rolling and Arrest of B16 Melanoma Cells Under Shear. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074287 | PubMed |
| 42063841 | Harnessing Membrane-Active Peptides for Selective Cancer Targeting: Phosphatidylserine Recognition by Tilapia Piscidin 4. | JACS Au | 2026 | https://conductscience.org/library/papers/42063841 | PubMed |
| 41813784 | CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/41813784 | PubMed |
| 41537901 | Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41537901 | PubMed |
| 41367861 | CD44 targeted functionalized nanocarriers for non-small cell lung cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/41367861 | PubMed |
| 40646591 | Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/40646591 | PubMed |
| 40335696 | Activation of lysosomal iron triggers ferroptosis in cancer. | Nature | 2025 | https://conductscience.org/library/papers/40335696 | PubMed |
| 40205882 | The progress of hyaluronic acid's application in therapeutic delivery. | Ther Deliv | 2025 | https://conductscience.org/library/papers/40205882 | PubMed |
| 39851489 | Hyaluronic Acid-Based Drug Delivery Systems for Cancer Therapy. | Cells | 2025 | https://conductscience.org/library/papers/39851489 | PubMed |
| 39273139 | Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39273139 | PubMed |
| 38826119 | Targeting the core program of metastasis with a novel drug combination. | Cancer Med | 2024 | https://conductscience.org/library/papers/38826119 | PubMed |
| 38790166 | CD44 Expression in Clear Cell Renal Cell Carcinoma (ccRCC) Correlates with Tumor Grade and Patient Survival and Is Affected by Gene Methylation. | Genes (Basel) | 2024 | https://conductscience.org/library/papers/38790166 | PubMed |
| 38672650 | CD44: A New Prognostic Marker in Colorectal Cancer? | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38672650 | PubMed |
| 38478335 | Surface Markers for the Identification of Cancer Stem Cells. | Methods Mol Biol | 2024 | https://conductscience.org/library/papers/38478335 | PubMed |
| 38039408 | Osteopontin induces mitochondrial biogenesis in deadherent cancer cells. | Oncotarget | 2023 | https://conductscience.org/library/papers/38039408 | PubMed |
| 37832027 | Plasmodium falciparum exploits CD44 as a coreceptor for erythrocyte invasion. | Blood | 2023 | https://conductscience.org/library/papers/37832027 | PubMed |
| 37489367 | Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas. | Antibodies (Basel) | 2023 | https://conductscience.org/library/papers/37489367 | PubMed |
| 37452042 | Long noncoding RNA LINC01594 inhibits the CELF6-mediated splicing of oncogenic CD44 variants to promote colorectal cancer metastasis. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37452042 | PubMed |
Data2
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1707342
GET https://conductscience.org/api/papers/v1/1707342/cited_by?page=2